Activated stat-3 in melanoma

Cancer Control

Volumn 15, Issue 3, 2008, Pages 196-201

  Messina, Jane L ^a   Yu, Hua ^c   Riker, Adam I ^b   Munster, Pamela N ^a   Jove, Richard L ^c   Daud, Adil I ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b University of South Alabama Mitchell Cancer Institute   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; ALPHA2B INTERFERON; INTERFERON RECEPTOR; STAT1 PROTEIN; STAT3 PROTEIN;

ARTICLE; CLINICAL ARTICLE; CONGENITAL NEVUS; CONTROLLED STUDY; DYSPLASTIC NEVUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MELANOCYTE; MELANOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SENTINEL LYMPH NODE; SKIN BIOPSY;

EID: 49649090913     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480801500302     Document Type: Article

References (24)

1. Bromberg J. Stat proteins and oncogenesis. J Clin Invest. 2002;109(9):1139-1142.
2. Bromberg J, Darnell JE Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene. 2000;19(21):2468-2473.
3. Wheatley K, Ives N, Eggermont A, et al. Interferon-α as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomized trials. J Clin Oncol. 2007;25(suppl). Abstract 8526.
4. Kirkwood JM. Building upon the standard of care in adjuvant therapy of high-risk melanoma. J Clin Oncol. 2005;23(34):8559-8563. Epub 2005 Oct 31.
5. Caraglia M, Marra M, Pelaia G, et al. Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol. 2005;202(2):323-335.
6. Pansky A, Hildebrand P, Fasler-Kan E, et al. Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int J Cancer. 2000;85(5):720-725.
7. Wong LH, Krauer KG, Hatzinisiriou I, et al. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J Biol Chem. 1997;272(45):79-85.
8. Li Z, Metze D, Nashan D, et al. Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol. 2004; 123(4):737-745.
9. Lesinski GB, Anghelina M, Zimmerer J, et al. The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse. J Clin Invest. 2003;112(2):170-180.
10. Badgwell B, Lesinski GB, Magro C, et al. The antitumor effects of interferon-alpha are maintained in mice challenged with a STAT1-deficient murine melanoma cell line. J Surg Res. 2004;116(1):129-136.
11. Lesinski GB, Valentino D, Hade EM, et al. Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy. Cancer Immunol Immunother. 2005;54(9):815-825. Epub 2005 Jan 25.
12. Kortylewski M, Jove R, Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev. 2005;24(2):315-327.
13. Niu G, Shain KH, Huang M, et al. Overexpression of a dominant-negative signal transducer and activator of transcription 3 variant in tumor cells leads to production of soluble factors that induce apoptosis and cell cycle arrest. Cancer Res. 2001;61(8):3276-3280.
14. Niu G, Bowman T, Huang M, et al. Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene. 2002;21(46):7001-7010.
15. Niu G, Heller R, Catlett-Falcone R, et al. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. 1999;59(20):5059-5063.
16. Kirkwood JM, Ibrahim J, Lawson DH, et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol. 2001;19(5):1430-1436.
17. Agarwala SS, Kirkwood JM. Adjuvant interferon treatment for melanoma. Hematol Oncol Clin North Am. 1998;12(4):823-883.
18. Xu Q, Briggs J, Park S, et al. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene. 2005;24(36):5552-5560.
19. Wang T, Niu G, Kortylewski M, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004;10(1):48-54. Epub 2003 Dec 21. Erratum in: Nat Med. 2004;10(2):209.
20. Homsi J, Cubitt C, Daud A. The Src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin Ther Targets. 2007;11(1):91-100.
21. Yu H, Jove R. The STATs of cancer: new molecular targets come of age. Nat Rev Cancer. 2004;4(2):97-105.
22. Vogel CL, Franco SX. Clinical experience with trastuzumab (Herceptin®). Breast J. 2003;9(6):452-462.
23. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol. 2005;23(11):2556-2568. Epub 2005 Mar 14.
24. Lynch TJ, Bell DW, Sordella R, et al Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129-2139. Epub 2004 Apr 29.